Evidence map›Paper›PMID 35865649›Full record

ArticleEngineering in life sciences2022

Optimization of a mAb production process with regard to robustness and product quality using quality by design principles.

Ole Jacob Wohlenberg, Carlotta Kortmann, Katharina V Meyer, Jana Schellenberg, Katharina Dahlmann, Janina Bahnemann, Thomas Scheper, Dörte Solle

Abstract read
In one paragraph

Article in Engineering in life sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ole Jacob WohlenbergInstitut für Technische Chemie Leibniz Universität Hannover Hannover Germany.
Carlotta KortmannInstitut für Technische Chemie Leibniz Universität Hannover Hannover Germany.
Katharina V MeyerInstitut für Technische Chemie Leibniz Universität Hannover Hannover Germany.
Jana SchellenbergInstitut für Technische Chemie Leibniz Universität Hannover Hannover Germany.
Katharina DahlmannInstitut für Technische Chemie Leibniz Universität Hannover Hannover Germany.
Janina BahnemannInstitut für Technische Chemie Leibniz Universität Hannover Hannover Germany.
Thomas ScheperInstitut für Technische Chemie Leibniz Universität Hannover Hannover Germany.
Dörte SolleInstitut für Technische Chemie Leibniz Universität Hannover Hannover Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quality by Design principles are well described and widely used in biopharmaceutical industry. The characterization of a monoclonal antibody (mAb) production process is crucial for novel process development and control. Yet, the application throughout the entire upstream process was rarely demonstrated. Following previously published research, this study marks the second step toward a complete process characterization and is focused on the effect of critical process parameters on the antibody production efficiency and quality of the process. In order to conduct the complex Design of Experiments approach with optimal control and comparability, the ambr®15 micro bioreactor platform was used. Investigated parameters included the pH and dissolved oxygen set points, the initial viable cell density (iVCD) as well as the N-1 duration. Various quality attributes (e.g., growth rate, viability, mAb titer, and peak proportion) were monitored and analyzed using multivariate data analysis to evaluate the parameter effects. The pH set point and the initial VCD were identified as key process parameters with strong influence on the cell growth as well as the mAb production and its proportion to the total protein concentration. For optimization and improvement in robustness of these quality attributes the pH must be increased to 7.2, while the iVCD must be lowered to 0.2 × 10

Indexed as

ambr®chinese hamster ovarymonoclonal antibodyprocess analytical technologyquality by design

Identifiers

PMID35865649
PMCPMC9288990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.